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We congratulate Boeckmans et al., on their comprehensive review of current models of non-
alcoholic fatty liver disease (NAFLD) presented ‘Human based systems: Mechanistic NASH 
modelling just around the corner?’ (1). NAFLD affects a large number of people worldwide and 
despite advances in our knowledge of the condition, further research is needed to identify 
biomarkers and target molecules for therapy. We agree that results from animal experiments may 
not always represent human pathophysiology accurately and we believe that relevant human in 
vitro models can be informative in understanding NAFLD disease mechanisms and target 
therapies. In addition, such models should help rationalisation of animal experiments in line with 
the 3R principles of replacement, reduction and refinement. 
We have developed a model of metabolic nutrient overload using the human hepatocyte 
HepG2/C3A cell line and have shown that treatment of these cells with energy substrates; lactate, 
pyruvate, octanoate and ammonia (LPON) recapitulates the sequence of hepatocellular events in 
dietary-induced NAFLD, including cytoplasmic fat accumulation, enhanced cellular respiration and 
increased production of reactive oxygen species leading to mitochondrial dysfunction [2, 3]. 
Furthermore, we have shown that media from fat-loaded C3A cells can activate stellate cells in 
vitro and thus represent a valid model for studying NAFLD pathophysiology (Figure 1, 
Supplementary data). The disadvantage, however, of C3A cells is the low expression of hepatic 
Cytochrome P450 (CYP) enzymes, while other key mediators of intermediary metabolism, such as 
the urea cycle-related enzymes, are also expressed at low levels. 
We feel that the value of the human hepatoma HepaRG cell line [4] as a putative in vitro disease 
model for NAFLD has perhaps been understated in the review (1), with HepaRG cells differing 
significantly to other hepatic cell lines mentioned: 
(i) HepaRG cells are originally derived from a female with a grade I well-differentiated 
hepatocellular carcinoma concurrent with hepatitis C and present under standard culture 
conditions as a 50:50 co-culture of hepatocyte and biliary epithelial cholangiocyte-like cells; 
(ii) HepaRG cells are highly-differentiated and express CYP enzymes and constitutive hepatic 
nuclear receptors at levels comparable to freshly-isolated primary human hepatocytes, without 
the need for inducers and also display other differentiated functions including intact ammonia 
metabolism and urea production pathways and functional bile canaliculi formation; 
(iii) HepaRG cells display a stable genotype and maintain phenotypically-differentiated functions in 
culture for at least four weeks, thus making them ideal cells for studying the pathophysiology of 
NAFLD [4, 5]. 
We have found HepaRG cells to be preferable to C3A cells within our nutrient overload model of 
NAFLD, and have shown that incubation of these cells with LPON or oleate induces cytoplasmic fat 
accumulation similar to that in C3A cells and in in dietary-induced NAFLD (Figure 2, Supplementary 
  
data). Co-culturing HepaRG cells with key pathophysiological players in liver disease such as 
mesenchymal stem cells, Kupffer and stellate cells could further optimise an in vitro model of 
NAFLD.  
Finally, utilising a NAFLD in vitro model in tandem with novel techniques, such as Electric Cell 
Substrate Impedance Sensing (ECIS), would permit, non-invasive, real-time study of cellular 
integrity and adhesion in fat-loaded cells and facilitate high throughput screening of novel 
compounds of therapeutic interest for NAFLD. 
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Figure 1: LX2 stellate cells exposed to supernatant from, LPON (2A&B) or oleate (3A&B) -
treated C3A cells showed enlargement and proliferation compared to untreated controls 
(1A&B). Phalloidin staining showed increase in cellular actin microfilaments (AM arrows). 
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Figure 2: A: Day 9 HepaRG cells treated with either oleate or lactate, pyruvate and 
octanoate (LPO) and stained with bodipy and hoescht. There is localised uptake of fat 
following both oleate and LPO treatments, with more cytoplasmic lipid staining following 
LPO treatment. B: Flow cytometry analysis of Day 10 HepaRG cells stained with PI showing 
no difference in level of viability between conditions. C: Flow cytometry of day 10 HepaRG 
cells staining for bodipy and CD49c showing that both hepatocytes, CD49c positive, and 
cholangiocytes have taken up both oleate and LPO.  
